A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology (Stage IIIB/IV) After Prior Chemotherapy

Trial Profile

A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology (Stage IIIB/IV) After Prior Chemotherapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms ENLARGE-Lung
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Mar 2017 Planned End Date changed from 1 Aug 2023 to 15 Aug 2023.
    • 30 Mar 2017 Planned primary completion date changed from 1 Aug 2023 to 15 Aug 2023.
    • 07 Oct 2016 Planned End Date changed from 1 Dec 2023 to 1 Aug 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top